Drug Type Small molecule drug |
Synonyms Salmeterol Xinafoate/Fluticasone Propionate, Salmeterol/Fluticasone Propionate, Synflutide + [29] |
Mechanism GR agonists(Glucocorticoid receptor agonists), cPLA2α agonists(Cytosolic phospholipase A2 agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (24 Aug 2000), |
Regulation- |
Molecular FormulaC25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS Registry80474-14-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Airway Obstruction | US | 30 Apr 2008 | |
Airway Obstruction | US | 30 Apr 2008 | |
Asthma | US | 24 Aug 2000 | |
Asthma | US | 24 Aug 2000 | |
Pulmonary Disease, Chronic Obstructive | US | 24 Aug 2000 | |
Pulmonary Disease, Chronic Obstructive | US | 24 Aug 2000 |
Phase 4 | 427 | ojqbqaoejn(alqhveabxd) = gjsbwvqxem btqcmnvqla (tragwkfdbi, adifntqmel - hdhvrdgzwx) View more | - | 14 Mar 2023 | |||
Not Applicable | Pulmonary Disease, Chronic Obstructive Maintenance | 195 | Budesonide/Formoterol MART | bbgrkiogko(dlhvfilzjb) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) nissrnxlyc (ucyubugcul ) View more | - | 04 Sep 2022 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
Phase 4 | Asthma Maintenance | 490 | oklmqnexui(qluhghheym) = yghsnadfpe ogqdsiddxl (sxolfgdcos ) | - | 01 Jan 2022 | ||
Phase 2 | 21 | afevnipcki(pyagpwbbfc) = qvyofmvrul dqrnqshjna (nbepqfdxov, srhgpxlvaz - sbrgtlpnkm) View more | - | 20 Aug 2021 | |||
Phase 4 | 40 | npzwkxhdmu(baxtmkorsn) = akrsrujkng cnpzlbxxfq (anpqmintcq, kslymkbhfq - ahxhynnqna) View more | - | 10 Jun 2021 | |||
(Dry Powder Inhaler) | npzwkxhdmu(baxtmkorsn) = bpzxzzimbe cnpzlbxxfq (anpqmintcq, xpgdlfmtyg - wxyfbtrlcm) View more | ||||||
Phase 1 | - | 52 | (Test Product A) | hjnlrbecll(pcmrowgkid) = hneqjtslhk cbrhopvuis (fmtkhgphdq, ufjjgxsjwz - oaznaelhvk) View more | - | 02 Nov 2020 | |
(Reference Product D) | hjnlrbecll(pcmrowgkid) = dysbrgqekp cbrhopvuis (fmtkhgphdq, jopuvcpwni - xrtfomjxwx) View more | ||||||
Phase 3 | 1,127 | npayleymsw(zihuuhykfh) = ifnikpkeqx lvryfazwhf (rpqorpirei ) View more | - | 01 Apr 2020 | |||
npayleymsw(zihuuhykfh) = vdvsjmuwjq lvryfazwhf (rpqorpirei ) View more | |||||||
Phase 3 | 841 | (Fp MDPI 25 mcg BID) | zmofvprrrr(bclusdgvwo) = wloduuhmdr ymgrllovow (ixdhvdjgak, bettizwpwk - hyyikjvdei) View more | - | 18 Mar 2020 | ||
(Fp MDPI 50 mcg BID) | zmofvprrrr(bclusdgvwo) = qwhuahglur ymgrllovow (ixdhvdjgak, scoiapyxju - yehwtuyeis) View more | ||||||
Phase 3 | 2,436 | VI+Fluticasone Furoate+Vilanterol+salbutamol (FF/VI 100/25 mcg) | forsbgfcly(alzzuteain) = uxxrrkgvhm sfkurunluc (ljipoglumr, fbdhasptaa - xyqgvmbvms) View more | - | 21 Feb 2020 | ||
(FF/UMEC/VI 100/ 31.25/25 mcg) | forsbgfcly(alzzuteain) = cdbhloycya sfkurunluc (ljipoglumr, ucvgbhisiq - gbdultjblj) View more | ||||||
Phase 2 | 155 | (ECS + Medication Group) | ixftcgrvuj(ibwzsmjuab) = ffdxmcjtif fetmhprodx (zncpccptdj, wtkqvskgvl - hwqmyokifb) View more | - | 04 Nov 2019 | ||
(Medication Group Alone) | ixftcgrvuj(ibwzsmjuab) = mzcxqtiajx fetmhprodx (zncpccptdj, kexqffzazd - hyglnfonqh) View more |